ClinicalTrials.gg

Program

zoldonrasib

Also written as “RMC-9805” and “Zoldonrasib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Colorectal Neoplasms, led by Revolution Medicines.

Furthest: phase 3, since May 26, 20266 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Revolution Medicines66 open or runningphase 3since May 26, 2026Aug 31, 2023Dec 31, 2026phase 1 · NCT06040541

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06040541 · 604 planned · United States
  2. Nov 30, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06162221 · 616 planned · United States, Australia, Austria and more
  3. May 20, 2024Phase 2 study in Colorectal NeoplasmsNCT06445062 · 1,130 planned · United States
  4. May 26, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07621718 · 670 planned · United States, Austria, Italy and more
  5. Aug 17, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07777822 · 430 planned · United States
  6. Sep 1, 2026Phase 3 study in Pancreatic NeoplasmsNCT07805954 · 400 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06040541
  2. Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06162221
  3. Sep 30, 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT06445062
  4. Dec 30, 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07621718

TargetBeta

KRAS →read by rule
“An orally bioavailable covalent tri-complex inhibitor of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07805954Pancreatic Neoplasms · United States3RecruitingMar 2029400
NCT07777822Carcinoma, Non-Small-Cell Lung · United States3RecruitingOct 2029430
NCT07621718Pancreatic Neoplasms · United States, Austria, Italy and more3RecruitingDec 30, 2028670
NCT06445062Colorectal Neoplasms · United States2RecruitingSep 30, 20281,130
NCT06162221Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more2RecruitingJun 2027616
NCT06040541Carcinoma, Non-Small-Cell Lung · United States1RecruitingDec 31, 2026604

How it is read

Names in the registry

  • “RMC-9805”, 3 entries
  • “zoldonrasib”, 2 entries
  • “Zoldonrasib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.